ClinicalTrials.Veeva

Menu
A

Artemis Institute for Clinical Research | Riverside, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY3298176
Tirzepatide
LY3526318
LY3857210
Simufilam
Donanemab
LY3556050
BI 1358894
IHL-42X

Parent organization

This site is a part of Artemis Institute for Clinical Research

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 14 total trials
Locations recently updated

A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-s...

Enrolling
Chronic Low-back Pain
Diabetic Neuropathic Pain
Drug: LY3016859 ISA
Drug: Placebo Oral
Locations recently updated

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Active, not recruiting
COVID-19
Influenza
Biological: COVID-19 Vaccine
Biological: Investigational influenza vaccine

The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RET...

Invitation-only
Alzheimer Disease
Drug: Simufilam

This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent seve...

Active, not recruiting
COVID-19
Biological: NVX-CoV2601 (5μg)
Biological: NVX-CoV2601 (35μg)

The goal of this randomised, double-blind phase II/III clinical trial is to determine the safety and efficacy of IHL-42X in subjects with obstructive...

Enrolling
Obstructive Sleep Apnea
Drug: Placebo
Drug: Acetazolamide

A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 we...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: Simufilam

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Active, not recruiting
Lower Respiratory Tract Illness
Biological: RSVpreF
Biological: Placebo

Trial sponsors

Lilly logo
C
BioNTech logo
Boehringer Ingelheim logo
I
Moderna logo
Novavax logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems